Ibrutinib (Imbruvica®, Pharmacyclics) is a once-daily oral therapy indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Ibrutinib is also indicated for the treatment of adult patients with CLL/SLL with 17p deletion.
Read efficacy study and prescribing information.
To help guide and assist patients during treatment, Pharmacyclics the YOU&iTM Support Program, which provides information on insurance coverage and out-of-pocket costs, and what to expect while on treatment.
Posted on 10/07/2020